A COMPARISON OF EFFICACY AND SAFETY OF KAYA KALPA VATI AND SEABUCK THORN OIL WITH ORAL METHOTREXATE AND TOPICAL STEROID IN CHRONIC PLAQUE PSORIASIS

A PROSPECTIVE, RANDOMIZED COMPARATIVE, CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KAYA KALPA VATI AND SEABUCK THORN OIL IN COMPARISION WITH ORAL METHOTREXATE AND TOPICAL STEROID IN CHRONIC PLAQUE PSORIASIS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/025658

Enrollment

122

Registered

2020-06-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: ORAL METHOTREXATE AND TOPICAL STEROID: Tablet Methotrexate , 15 mg, 1 tab per oral per week for 16 weeks. Mometasone cream twice daily application over skin lesion for 16 weeks. Control

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient with chronic plaque psoriasis. 2.Psoriasis of both sex and age group more than 18 years. 3.All newly diagnosed and old cases of psoriasis. 4.Patients with PASI(psoriasis area severity index) score above10-12. 5.Patients with involvement of >10% body surface area.

Exclusion criteria

Exclusion criteria: 1. Patient who do not give consent for the study. 2. Patient on any therapy of psoriasis for past 3 months. 3.Patient having any other chronic debilitating diseases or other chronic skin disorders.

Design outcomes

Primary

Measure	Time frame
Reduction in PASI score Improvement in DLQITimepoint: 8weeks	—

Secondary

Measure	Time frame
Reduction in PASI score Improvement in DLQITimepoint: 16 weeks	—

Countries

India

Contacts

Public ContactDr Meenakshi Sharma

National institute of medical science

drshilpysavi@yahoo.com9509097801

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026